Cost-Effectiveness Model of Use of Genetic Testing as an Aid in Assessing the Likely Benefit of Aspirin Therapy for Primary Prevention of Cardiovascular Disease

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1387-1394

  Shiffman, Dov ^a   Slawsky, Katherine ^b,c   Fusfeld, Lauren ^b,c   Devlin, James J ^a   Goss, Thomas F ^b,c  

^a CELERA   (United States)

^b Boston Healthcare Associates Inc   (United States)

^c Boston Healthcare Associates Inc   (United States)

Author keywords

Aspirin primary prevention; Cardiovascular disease; Cost effectiveness; LPA genotype testing

Indexed keywords

ACETYLSALICYLIC ACID; LPA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAMINGHAM RISK SCORE; GASTROINTESTINAL HEMORRHAGE; GENETIC SCREENING; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; QUALITY OF LIFE; STROKE;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION;

EID: 84862123605     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.004     Document Type: Article

References (20)

1. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 30:1849-1860.
2. Seshasai S.R., Wijesuriya S., Sivakumaran R., et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:209-216. [Epub ahead of print].
3. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009, 150:396-404. US Preventive Services Task Force.
4. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
5. Schunkert H., König I.R., Kathiresan S., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genetics 2011, 43:333-338.
6. Peden J.F., Farrall M. Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum Mol Genet 2011, 20:R198-R205.
7. Chasman D.I., Shiffman D., Zee R.Y., et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009, 203:371-376.
8. Li Y., Luke M.M., Shiffman D., Devlin J.J. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet 2011, 4:565-573.
9. National Health and Nutrition Examination Survey Data National Center for Health Statistics, Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005-2006, Accessed August 31, 2010. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm.
10. Accessed August 31, 2010. http://www.framinghamheartstudy.org/risk/gencardio.html.
11. Glasser S.P., Cushman M., Prineas R., et al. Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?. Prev Med 2008, 47:161-166.
12. Accessed August 31, 2010. http://cost.jsc.nasa.gov/inflateGDP.html.
13. Pignone M., Earnshaw S., Pletcher M.J., Tice J.A. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007, 167:290-295.
14. Latimer N., Lord J., Grant R.L., et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009, 339:b2538. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.
15. Nherera L., Calvert N.W., DeMott K., et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010, 26:529-536.
16. Straube S., Tramer M.R., Moore R.A., et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009, 9:41.
17. Rosamond W.D., Folsom A.R., Chambless L.E., et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30:736-743.
18. Roger V., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics, 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, [published corrections appear in Circulation. 2011;123:e240 and Circulation. 2011;124:e426].
19. Quinn R.R., Naimark D.M.J., Oliver M.J., Bayoumi A.M. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation?. a cost-utility analysis. Am J Kidney Dis 2007, 50:421-432.
20. Sanders G.D., Kong M.H., Al-Khatib S.M., Peterson E.D. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J 2010, 160:122-131.